News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase 2 Results for Nano-formulated NSAIDs under Development at Iroko Pharmaceuticals to Be Reported at American College of Rheumatology Meeting



11/4/2011 7:38:54 AM

PHILADELPHIA--(BUSINESS WIRE)--The results of the Phase 2 program sponsored by Iroko Pharmaceuticals to develop novel, lower-dose formulations of a widely used class of pain medicines will be reported November 7th at the annual meeting of the American College of Rheumatology (ACR) in Chicago.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES